Evidence map›Paper›PMID 39531203›Full record

ArticleInternational journal of hematology2025

CD34

Ayano Fukui-Morimoto, Kentaro Serizawa, Ko Fujimoto, Aki Hanamoto, Yoshio Iwata, Hiroaki Kakutani, Takahiro Kumode, Chikara Hirase, Yasuyoshi Morita, Yoichi Tatsumi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ayano Fukui-MorimotoDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Kentaro SerizawaDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan. serizawa@med.kindai.ac.jp.
Ko FujimotoDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Aki HanamotoDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Yoshio IwataDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Hiroaki KakutaniDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Takahiro KumodeDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Chikara HiraseDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Yasuyoshi MoritaDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Yoichi TatsumiDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Hitoshi HanamotoDepartment of Hematology, Kindai University Nara Hospital, Ikoma, Nara, Japan.
Hirokazu TanakaDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 5898511, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the introduction of new drugs, multiple myeloma (MM) still remains incurable. We previously reported that CD34

Indexed as

4-1BB LigandAntigens, CD34Immune Checkpoint ProteinsMultiple MyelomaFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle Aged4-1BB LigandAntigens, CD34Immune Checkpoint ProteinsCD137CD34Immune-checkpoint inhibitorsMultiple myelomaMyeloma-initiating cellsTIGIT

Identifiers

PMID39531203
PMCPMC11742359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.